5-Amino-1MQ vs Selank: Mechanism, Half-Life & Research Use

Q: What purity levels does PX1 Research guarantee for these compounds?

PX1 Research supplies 5-Amino-1MQ and Selank at ≥99% purity as confirmed by HPLC and Mass Spectrometry analysis performed in ISO 17025 accredited, independent US laboratories.

Q: Are these compounds approved for human consumption or therapeutic use?

No. 5-Amino-1MQ and Selank are strictly sold for in vitro laboratory evaluation and preclinical animal research. They are not intended, labeled, or approved for human, clinical, or veterinary applications.

Q: What are the recommended storage conditions for lyophilized peptides?

Lyophilized powder vials should be stored at -20°C upon receipt, protected from light and moisture. Reconstituted aqueous peptide solutions should be aliquoted and kept at -80°C to minimize degradation from freeze-thaw cycles.

Q: Where can I locate the Certificate of Analysis (COA) for my lot?

Batch-specific Certificates of Analysis including HPLC chromatograms and mass spectra are accessible directly via the PX1 Research COA lookup portal using your lot number.

Evaluating candidate molecules for cellular bioenergetics versus neurochemical modulation requires an understanding of their underlying biochemical pathways. This comparative analysis examines 5-Amino-1MQ—a selective small-molecule inhibitor of nicotinamide N-methyltransferase—alongside Selank, a synthetic heptapeptide derived from tuftsin, detailing their distinct mechanisms, pharmacokinetics, and experimental applications in laboratory settings.

GMP-compliant U.S. facilities

ISO 17025 third-party COAs

100% domestic — no imports

Fast tracked domestic shipping

Shop research peptides

Quick answer

Reviewed by PX1 Research scientific team

Key takeaways

[5-Amino-1MQ](/research-peptides/5-amino-1mq) and [Selank](/research-peptides/selank) represent fundamentally distinct research tools: 5-Amino-1MQ is a small-molecule, membrane-permeable inhibitor of nicotinamide N-methyltransferase (NNMT) targeted at intracellular [NAD+](/research-peptides/nad-plus) salvage and cellular bioenergetics, whereas Selank is a synthetic heptapeptide derivative of tuftsin engineered to modulate GABAergic neurotransmission, BDNF expression, and inflammatory pathways in central nervous system research.
| Criteria | [5-Amino-1MQ](/research-peptides/5-amino-1mq) | [Selank](/research-peptides/selank) | | :--- | :--- | :--- | | **Mechanistic Class** | Small-Molecule NNMT Inhibitor | Synthetic Neuropeptide (Tuftsin Analog) | | **Primary Receptor / Target** | Nicotinamide N-Methyltransferase (NNMT) | GABA-A Allosteric Sites / BDNF Receptors | | **Reported In Vitro / In Vivo Half-Life** | ~1.5 to 4 hours (plasma/tissue dependent) | ~2 to 10 minutes (rapid enzymatic cleavage) | | **Solubility Profile** | DMSO / Ethanol / Solubilized Buffers | Aqueous Buffers (Bacteriostatic Water / PBS) | | **Primary Preclinical Models** | Diet-Induced Obesity Rodents, Myoblast Assays | Rodent Behavioral / Neurochemical Models | | **Primary Assay Focus** | Intracellular [NAD+](/research-peptides/nad-plus) / Mitochondrial Oxygen Consumption | Neurotransmitter Flux / Brain-Derived Neurotrophic Factor | | **Common Laboratory Formats** | Lyophilized Powder (5mg, 10mg) | Lyophilized Powder (5mg, 10mg) |
From a structural standpoint, [5-Amino-1MQ](/product/5-amino-1mq-5mg) is a quinoline derivative (5-amino-1-methylquinolinium) engineered to bind competitively within the catalytic site of NNMT.
Nicotinamide N-methyltransferase (NNMT) is a cytosolic enzyme that transfers a methyl group from S-adenosylmethionine (SAM) to nicotinamide (NAM), producing 1-methylnicotinamide (1-MNA) and S-adenosylhomocysteine (SAH).

Direct Comparison: 5-Amino-1MQ vs Selank

5-Amino-1MQ and Selank represent fundamentally distinct research tools: 5-Amino-1MQ is a small-molecule, membrane-permeable inhibitor of nicotinamide N-methyltransferase (NNMT) targeted at intracellular NAD+ salvage and cellular bioenergetics, whereas Selank is a synthetic heptapeptide derivative of tuftsin engineered to modulate GABAergic neurotransmission, BDNF expression, and inflammatory pathways in central nervous system research.

While both compounds are investigated in translational biology, their target substrates, molecular structures, and primary physiological endpoints do not overlap. Researchers evaluating metabolic flux, adipose tissue dynamics, and mitochondrial capacity typically select NNMT inhibitors like 5-Amino-1MQ, whereas investigators focused on neuroprotection, anxiolytic-like behavioral paradigms, and neuropeptide processing utilize Selank.

Comparative Criteria Summary Table

This breakdown highlights why laboratory protocols cannot treat these two reagents interchangeably. Selecting between them depends on whether the investigative hypothesis centers on enzymatic methyl-donor dynamics or central neuropeptidergic signaling cascades.

Molecular Structure and Biochemical Classification

From a structural standpoint, 5-Amino-1MQ is a quinoline derivative (5-amino-1-methylquinolinium) engineered to bind competitively within the catalytic site of NNMT. Because it is a non-peptidic small molecule, it exhibits distinct membrane permeability profiles and chemical stability compared to traditional amino acid chains. Its chemical structure allows for direct cellular entry without relying on specialized peptide transporters.

In contrast, Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. Formulated by extending the endogenous tetrapeptide tuftsin with a Pro-Gly-Pro tripeptide sequence at the C-terminus, Selank exhibits enhanced metabolic stability against endopeptidases relative to native tuftsin. However, as a peptide, its tertiary stability in aqueous solution remains subject to proteolytic cleavage, requiring precise storage and handling protocols as outlined in our broad catalog of research peptides.

5-Amino-1MQ Mechanism: NNMT Inhibition and Bioenergetics

Nicotinamide N-methyltransferase (NNMT) is a cytosolic enzyme that transfers a methyl group from S-adenosylmethionine (SAM) to nicotinamide (NAM), producing 1-methylnicotinamide (1-MNA) and S-adenosylhomocysteine (SAH). In metabolic tissue models, elevated NNMT activity drains the cellular pool of nicotinamide, impairing the salvage pathway responsible for synthesizing nicotinamide adenine dinucleotide (NAD+).

Preclinical studies suggest that applying 5-Amino-1MQ to cultured adipocytes or administering it in high-fat diet rodent models selectively blocks NNMT activity. This inhibition prevents the irreversible methylation of nicotinamide, thereby increasing intracellular NAD+ availability and promoting SAM preservation. Consequently, cellular assays demonstrate enhanced mitochondrial oxygen consumption rates (OCR), upregulated sirtuin-1 (SIRT1) expression, and altered lipid accumulation. Researchers investigating metabolic decay, skeletal muscle bioenergetics, and mitochondrial efficiency frequently utilize 5-Amino-1MQ alongside mitochondrial-targeted compounds such as MOTS-c.

Selank Mechanism: Neurotropic and Immunomodulatory Pathways

Selank operates through central neurochemical and neurotrophic channels. In vitro binding studies indicate that Selank acts as a subtle allosteric modulator of the GABA-A receptor complex, influencing GABAergic affinity without displaying the sedating or non-selective binding profile of classical benzodiazepines. This modulation alters monoamine neurotransmitter turnover—specifically altering serotonin (5-HT) and dopamine metabolism in limbic structures.

Furthermore, preclinical research demonstrates that Selank upregulates mRNA expression of Brain-Derived Neurotrophic Factor (BDNF) and Nerve Growth Factor (NGF) in hippocampal tissue. Additional data suggest it inhibits enkephalin-degrading enzymes, prolonging endogenous opioid peptide activity in stress-induced animal models. Researchers focused on neurodegenerative models, cognitive performance assays, and neuro-immune interactions often evaluate Selank in parallel with related neuroactive peptides like Semax.

Half-Life, Stability, and Metabolic Fate

Understanding the degradation kinetics of 5-Amino-1MQ and Selank is vital for designing reproducible dosing regimens in preclinical research. 5-Amino-1MQ, as a small-molecule quinoline, exhibits a relatively prolonged elimination half-life in rodent models, typically ranging between 1.5 and 4 hours depending on the matrix and route of administration. It is primarily cleared via renal filtration and hepatic phase II conjugation pathways, maintaining intracellular concentrations sufficient to sustain enzymatic inhibition over extended incubation windows.

Conversely, Selank undergoes rapid enzymatic hydrolysis in systemic circulation. Unmodified heptapeptides generally exhibit plasma half-lives of under 10 minutes due to abundant serum carboxypeptidases and aminopeptidases. However, the C-terminal Pro-Gly-Pro sequence in Selank confers partial resistance, allowing steady-state levels to persist longer in central nervous tissue than native tuftsin. When conducting liquid phase assays or cellular incubations, researchers must account for these metabolic half-lives to maintain valid experimental concentrations.

In Vitro and Animal Study Findings

In vivo investigations utilizing rodent models of diet-induced obesity demonstrate that NNMT inhibition via 5-Amino-1MQ leads to reduced body weight gain, decreased adipocyte volume, and enhanced insulin sensitivity parameters without altering caloric intake. In vitro myoblast cultures treated with 5-Amino-1MQ exhibit enhanced cellular proliferation and increased ATP generation, confirming its utility in skeletal muscle regeneration research.

Selank research in animal models predominantly features elevated plus maze, open field, and passive avoidance testing. Rodent data show significant reductions in anxiety-like behaviors and stress-induced inflammatory cytokine release (such as IL-6 and TNF-alpha). In vitro neuronal cultures exposed to Selank demonstrate enhanced neurite outgrowth and protective effects against oxidative stress, supporting its role in neuroprotective compound screening.

Comparative Analysis: Metabolic vs. Neurological Peptide Classes

When designing multi-compound experimental matrices, researchers often categorize reagents by target system. For studies examining cellular respiration, energy expenditure, and lipid regulation, 5-Amino-1MQ is frequently evaluated alongside metabolic agents such as MOTS-c and targeted weight-management research compounds like AOD-9604. These compounds act on intracellular signaling cascades governing mitochondrial respiration and lipolytic enzymatic activity.

Conversely, when constructing assays focused on central nervous system repair, memory consolidation, or neuroinflammation, researchers place Selank alongside neuropeptides such as Semax. While metabolic compounds modify cellular substrate utilization, neuroactive peptides modify synaptic plasticity and neurotrophin expression. Selecting the correct compound requires mapping your model's primary endpoints—whether measuring intracellular NAD+/NADH ratios or quantifying central monoamine concentrations.

Study Design Selection: Matching Compounds to Hypotheses

To optimize resource allocation and ensure rigorous control groups, researchers should align their choice of material with their primary research questions:

• **Select 5-Amino-1MQ if your study design involves:** Measuring NNMT activity, evaluating intracellular NAD+ elevation, analyzing adipocyte hyperplasticity, monitoring mitochondrial oxygen consumption (OCR), or evaluating skeletal muscle endurance in metabolic defect models. • **Select Selank if your study design involves:** Assessing GABAergic receptor modulation, measuring neurotrophin upregulation (BDNF/NGF), evaluating behavioral paradigms of stress and anxiety in rodents, or studying neuropeptide-mediated immunomodulation. • **Consider cross-domain designs:** Projects studying the metabolic-neurodegenerative axis (e.g., neuro-metabolic decline) may deploy both compounds in separate experimental arms to compare systemic metabolic support versus central neurotrophic signaling.

Reconstitution, Handling, and Quality Assurance Protocols

Proper preparation of reference materials is essential for experimental accuracy. Because 5-Amino-1MQ is a small-molecule salt, its solubility varies significantly based on vehicle choice; while moderately soluble in aqueous buffers, stock solutions are frequently prepared in laboratory-grade DMSO or ethanol prior to dilution in assay media. Selank, as a hydrophilic heptapeptide, dissolves readily in sterile or bacteriostatic water.

To calculate precise working concentrations and solvent ratios for your assays, utilize our online reconstitution calculator. All reference materials supplied by PX1 Research undergo rigorous quality verification in ISO 17025 accredited laboratories. Every lot is verified via High-Performance Liquid Chromatography (HPLC) and Mass Spectrometry (MS) to guarantee chemical purity exceeding 99% and to ensure low endotoxin levels. Researchers can review batch-specific analytical documentation via our COA database, or discuss institutional volume requirements through our wholesale account portal. For further deep dives into comparative peptide literature, visit the PX1 research library hub.

Frequently Asked Questions

Is 5-Amino-1MQ a peptide?

No. 5-Amino-1MQ is a small-molecule quinoline derivative (5-amino-1-methylquinolinium) that acts as a synthetic inhibitor of the enzyme nicotinamide N-methyltransferase (NNMT). It does not contain amino acid residues or peptide bonds.

What is the primary biological target of Selank?

Selank primarily targets central neurochemical pathways, acting as an allosteric modulator of GABA-A receptors, upregulating mRNA expression of Brain-Derived Neurotrophic Factor (BDNF), and inhibiting enkephalin-degrading enzymes in neuronal tissue.

Can 5-Amino-1MQ and Selank be used in the same experimental model?

Yes, provided the experimental hypothesis explores neuro-metabolic crosstalk. However, because their mechanisms, solubility profiles, and metabolic clearance rates differ fundamentally, they must be administered and analyzed under distinct parameters and control conditions.

How should 5-Amino-1MQ be reconstituted for cell culture assays?

5-Amino-1MQ is typically dissolved in high-purity DMSO to create a concentrated stock solution before diluting into culture media. Researchers should verify final DMSO concentrations remain below cytotoxic thresholds (<0.1% v/v in most cell lines).

What purity levels does PX1 Research guarantee for these compounds?